Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
889 studies found for:    Open Studies | "Hypoglycemic Agents"
Show Display Options
Rank Status Study
21 Recruiting Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
22 Recruiting Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
23 Recruiting An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada
Condition: Diabetes Mellitus, Type 2
Intervention: Other: No Intervention
24 Recruiting Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
25 Not yet recruiting A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Mosapride;   Drug: Placebo
26 Not yet recruiting Effects of Nutrition Meal Replacement and Individualized Exercise Prescription on Type 2 Diabetes
Conditions: Overweight;   Obesity;   Type2 Diabetes
Intervention: Dietary Supplement: nutritional meal replacement
27 Recruiting Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes
Conditions: Cystic Fibrosis;   Cystic Fibrosis Related Diabetes
Interventions: Other: Oral Glucose Tolerance Test;   Other: Mixed Meal Tolerance Test;   Other: Hypoglycemic Clamp
28 Recruiting A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec
29 Recruiting A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: Insulin degludec/insulin aspart;   Drug: Insulin glargine;   Drug: Insulin aspart
30 Recruiting Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Behavioral: Active titration algorithm;   Behavioral: Usual titration algorithm
31 Recruiting Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis
Conditions: Cirrhosis;   Diabetes Mellitus, Type 2
Intervention: Device: Continuous glucose monitor (Dexcom, San Diego, CA)
32 Recruiting A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: INSULIN GLARGINE (U300);   Drug: metformin;   Drug: sulfonylurea;   Drug: meglitinides;   Drug: thiazolidinediones;   Drug: alpha-glucosidase inhibitors;   Drug: GLP1 Receptor Agonist;   Drug: Dipeptidyl peptidase-IV (DPP-IV) inhibitors;   Drug: Sodium-glucose transport-2 (SGLT-2) inhibitors
33 Recruiting Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes
Interventions: Drug: Dehydroepiandrosterone;   Drug: Placebo
34 Recruiting Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
35 Recruiting Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Exenatide;   Drug: Glargine;   Drug: Oral antidiabetic drugs;   Drug: Rapid-acting insulin analogs
36 Recruiting A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes
Conditions: Type 1 Diabetes;   Hypoglycemia Unawareness
Interventions: Drug: N-acetyl cysteine;   Drug: Placebo
37 Recruiting Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: INSULIN GLARGINE
38 Recruiting Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)
Condition: Polycystic Ovary Syndrome (PCOS)
Interventions: Drug: DLBS3233;   Drug: Metformin XR;   Drug: Placebo caplet of Metformin XR;   Drug: Placebo capsule of DLBS3233
39 Recruiting The Effect of Intensive Multifactorial Therapy on Endothelial Function in Newly Diagnosed Type 2 Diabetes
Condition: Endothelial Dysfunction
Interventions: Drug: Intensive multifactorial group;   Drug: conventional multifactorial therapy group
40 Recruiting A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Dulaglutide;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.